Abstract: Objective To evaluate clinical efficacy and adverse events of oxaliplatin（OXA）-based regimen for patients with sorafenib-resistant advanced primary liver carcinoma. Methods Patients with sorafenib-resistant advanced primary liver carcinoma were treated with FOLFOX 4 or XELOX regimens. FOLFOX regimen was given as follow： OXA 85mg／m2 iv，d1； calcium folinate 200mg／m2 iv， d1， d2； fluorouracil（5-FU）400mg／m2 bolus，d1，d2；5-FU 600mg／m2 civ, d1，d2. Two weeks was a cycle. XELOX regimen was applied as follow： OXA 130mg／m2 iv， d1； capecitabine 1250mg／m2 twice daily with oral administration，d1-d14. Three weeks was a cycle. Tumor evaluation for FOLFOX 4 regimen was performed every 3 cycles and XELOX regimen was every 2 cycles. The time to progression（TTP）and overall survival（OS）were observed. Toxicities were evaluated according to NCI CTC 3.0. Serum α-fetoprotein（AFP）level was also monitored according to the schedule. HBV DNA was monitored for patients with HBV. ResultsThe efficacy of 13 patients could be evaluated. No one achieved CR， PR in 2 patients， SD in 6 patients and PD in 4 patients. The response rate and disease control rate were 15.4％ and 61.5％， respectively. The median TTP was 110 days and the median OS was 225 days. AFP decreased rate was 38.5％. Hepatitis B virus reactivation was observed in 2 patients， and decreased to normal while receiving anti-HBV therapy. The main adverse event is myelosuppression including leucopenia and thrombocytopenia. Other adverse events including nausea， vomiting， liver injury， periphery and neurotoxicity were well-tolerated. Conclusion FOLFOX 4 or XELOX regimen for patients with sorafenib resistant advanced primary liver carcinoma is effective and well-tolerable and further study should be taken to observe.